Complete molecular remission induced by concomitant Cladribine-Rituximab treatment in a case of multi-resistant hairy cell leukemia

Leukemia and Lymphoma

Volumn 48, Issue 12, 2007, Pages 2441-2443

  Forconi, Francesco ^a   Toraldo, Francesca ^a   Sozzi, Elisa ^a   Amato, Teresa ^a   Raspadori, Donatella ^a   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; PENTOSTATIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER RESISTANCE; CASE REPORT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOPHENOTYPING; INFECTION; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED;

EID: 37149031235     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701647903     Document Type: Article

References (12)

1. Lauria, F. and Forconi, F. (2004) Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother, 5, pp. 1523-1533.
2. Tallman, M. S., Hakimian, D., Rademaker, A. W., Zanzig, C., Wollins, E. and Rose, E. (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience. Blood, 88, pp. 1954-1959.
3. Dearden, C. and Else, M. (2006) Hairy cell leukemia. Curr Oncol Rep, 8, pp. 337-342.
4. Nieva, J., Bethel, K. and Saven, A. (2003) Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood, 102, pp. 810-813.
5. Lauria, F., Lenoci, M., Annino, L., Raspadori, D., Marotta, G. and Bocchia, M. (2001) Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica, 86, pp. 1046-1050.
6. Thomas, D. A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M. J. and Giles, F. J. (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood, 102, pp. 3906-3911.
7. Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N. and Caracciolo, F. (2004) Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol, 73, pp. 412-417.
8. Ravandi, F., Jorgensen, J. L., O'Brien, S. M., Verstovsek, S., Koller, C. A. and Faderl, S. (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood, 107, pp. 4658-4662.
9. Chow, K. U., Sommerlad, W. D., Boehrer, S., Schneider, B., Seipelt, G. and Rummel, M. J. (2002) Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica, 87, pp. 33-43.
10. Byrd, J. C., Peterson, B. L., Morrison, V. A., Park, K., Jacobson, R. and Hoke, E. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, pp. 6-14.
11. Forconi, F., Sozzi, E., Raspadori, D., Toraldo, F., Defina, M. and Zaja, F. (2006) Hairy cell leukemia (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes. Blood, 108, p. 659a.
12. van Dongen, J. J., Langerak, A. W., Bruggemann, M., Evans, P. A., Hummel, M. and Lavender, F. L. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia, 17, pp. 2257-2317.